Tag - Corbus Pharmaceuticals

Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the European Commission has granted Orphan Designation in the European Union (“EU”) for the Company’s novel synthetic oral endocannabinoid-mimetic drug, JBT-101 (“Resunab”) for the treatment of systemic sclerosis. Read more >>

Why Corbus Pharmaceuticals Holdings, Inc. Stock Rocketed 412% Upwards in 2016

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) thrilled investors with a 412.1% gain last year, according todata from S&P Global Market Intelligence Opens a New Window. . Positive mid-stage clinical trial results for its lead drug, Resunab, lifted the stock and ignited hope for further expansion in the future. Read more >>

Shares Bringing Holiday Cheer For Investors: Corbus Pharmaceuticals Holdings, Inc.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have climbed in the previous month. During that time period, shares are up 6.88% which has provided some nice profits for investors who may be looking to take advantage of the recent gains. Focusing in on the past five trading days, shares have changed 4.27%. Year-to-date, the stock has performed 418.18%. Read more >>

Top Earnings Report to Watch for: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is trading up 726.73% versus 12-month low of 1.01 and stands -22.54% lower from its 1-year peak of $10.78. The consensus price target (PT) of $17.00 means that the market expects Company shares to increase by 101.2% in the short run. The sell-side target prices range from $12 to $20. In the last month the stock has moved in price 5.03%, with a one year change of 412.27%. The last trading session volume compares […]

Two Biotech Stocks Are Just So Hot Right Now (Corbus Pharmaceuticals Holdings, Inc.)

On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. Read more >>

Corbus Pharmaceuticals Announces Completion of Phase 2 Study of Resunab for Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed the Phase 2 study evaluating Resunab for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). Corbus expects to report topline data from this study in the fourth quarter of 2016. Read more >>

Hot Biotech Stocks To Watch Right Now: Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings, Inc. (CRBP) a clinical stage drug development company targeting rare, chronic and serious inflammatory and fibrotic diseases, announced that Professor Derek Gilroy, Ph.D. presented data on the effects of Resunab in a model of inflammation in healthy volunteers on September 28, 2016. The presentation was made at the 6th European Workshop on Lipid Mediators at Goethe University in Frankfurt am Main, Germany. Read more >>